146,214 Shares in Lantheus Holdings Inc (NASDAQ:LNTH) Acquired by Landscape Capital Management L.L.C.

Share on StockTwits

Landscape Capital Management L.L.C. purchased a new position in Lantheus Holdings Inc (NASDAQ:LNTH) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 146,214 shares of the medical equipment provider’s stock, valued at approximately $4,138,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of LNTH. First Quadrant L P CA purchased a new position in Lantheus in the 1st quarter worth approximately $95,000. Aperio Group LLC purchased a new stake in shares of Lantheus during the 2nd quarter worth approximately $109,000. Anderson Fisher LLC purchased a new stake in shares of Lantheus during the 1st quarter worth approximately $112,000. Meeder Asset Management Inc. raised its holdings in shares of Lantheus by 212.8% during the 1st quarter. Meeder Asset Management Inc. now owns 4,757 shares of the medical equipment provider’s stock worth $115,000 after acquiring an additional 3,236 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in shares of Lantheus during the 4th quarter worth approximately $171,000. 91.35% of the stock is currently owned by institutional investors.

In related news, CEO Mary Anne Heino sold 16,827 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $23.89, for a total transaction of $401,997.03. Following the sale, the chief executive officer now owns 637,762 shares in the company, valued at approximately $15,236,134.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sam R. Leno sold 3,950 shares of the stock in a transaction on Friday, June 7th. The shares were sold at an average price of $25.33, for a total value of $100,053.50. Following the sale, the director now owns 49,580 shares in the company, valued at approximately $1,255,861.40. The disclosure for this sale can be found here. Insiders have sold a total of 136,187 shares of company stock worth $3,604,063 in the last 90 days. 2.60% of the stock is currently owned by insiders.

LNTH has been the topic of several recent research reports. Zacks Investment Research cut Lantheus from a “hold” rating to a “sell” rating in a report on Friday, August 2nd. ValuEngine cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, BidaskClub cut Lantheus from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 11th.

NASDAQ:LNTH traded up $0.18 during midday trading on Thursday, hitting $21.48. 6,706 shares of the company traded hands, compared to its average volume of 491,893. The firm has a fifty day moving average price of $25.84. Lantheus Holdings Inc has a 12-month low of $12.59 and a 12-month high of $29.80. The stock has a market cap of $863.75 million, a price-to-earnings ratio of 22.81, a P/E/G ratio of 1.76 and a beta of 1.47. The company has a debt-to-equity ratio of 2.05, a current ratio of 2.62 and a quick ratio of 2.01.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.27 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. Lantheus had a return on equity of 51.08% and a net margin of 11.20%. The company had revenue of $85.70 million for the quarter, compared to analyst estimates of $88.72 million. During the same quarter in the prior year, the firm posted $0.25 EPS. Lantheus’s quarterly revenue was up .1% compared to the same quarter last year. On average, analysts anticipate that Lantheus Holdings Inc will post 1.06 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Recommended Story: Why do companies issue convertible shares?

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.